Volume 2
ISBN: 978-93-87500-46-4
Cancer that develops from breast tissue is called as Breast Cancer. It is the most common invasive cancer in females. There are different types of breast cancer and they usually starts in ducts, lobules or tissues. Open Access eBooks is publishing an eBook on breast cancer entitled RECENT STUDIES & ADVANCES IN BREAST CANCER. Researchers working on these areas are requested to contribute their work for the publication in volume 1.
All received book chapters undergo review process and are published on our website in PDF and HTML formats. Each volume contains around 5 or 6 book chapters providing information on latest advances in treating breast cancer.
Benefits of publishing with us:
Universal Access: eBooks published in Open Access eBooks gain international visibility. No region barriers and content is accessed by everyone across the world from our website. We also deposit published eBooks in different databases.
Freely Available: Open Access eBooks follows the principles of Open Access and the content is available to the readers without any cost. Readers can read, share, and store the published ebooks/book chapters.
Copyright with Authors: As an eBook publisher, we serve researchers in publishing their valuable work after the stringent review process. However, copyright lies with authors. We follow the CC-BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/3.0/).
Different Formats: We provide eBooks in PDF and HTML formats. Both formats are user friendly and can act as per the user requirements. We put our efforts to provide other formats in future.
For more information, contact info@openaccessebooks.com
Published Chapters:
Recent Studies and Advances in Breast Cancer
Author(s): Edna Kapenhas, MD*; Phillip Kyle Summers, DO
Breast cancer is the most common cancer affecting women, accounting for approximately 30% of all new cancer diagnoses in the United States. It is estimated that 1 in 8 women will develop breast cancer in their lifetime. In the United States in 2017, an estimated 255,180 new cases of breast cancer and 63,410 cases of carcinoma in situ of the female breast will be diagnosed. However, Due to Major advances in breast cancer diagnosis, management, and treatment, breast cancer has been surpassed by lung cancer (as of 2013) as the most deadly female cancer. In 2017, 41,070 of the expected new cases, will die of breast cancer, which calculates out to an 84% survival rate. While the overall incidence of breast cancer has slightly increased since 2004, the death rate for female breast cancer dropped 38% from 1989 to 2014, further validating our improvements in breast cancer treatment.
Chemoprevention in Breast Cancer
Author(s): Unmesh Vidyadhar Takalkar*; Manisha Unmesh Takalkar*; Suresh Advani
Breast cancer is the most frequently diagnosed cancer among women worldwide. It represents the significant health problem imposing an enormous socioeconomic burden on healthcare system. Among cancer related deaths, breast cancer is the second leading cause of death. Its global incidence and clinicopathological presentation varies markedly depending on the region and ethnicity, being highest in western developed countries. But because of modernization, dramatically changed lifestyle and altered pattern of reproductive behavior, prevalence of breast cancer is rising in the developing countries also.
Targeted Therapies in Triple Negative Breast Cancer: Current Knowledge and Perspectives
Author(s): Marina Cruz-Lozano1, Adrián González-González1, Esperanza Muñoz-Muela1, Francisca E Cara1, Sergio Granados-Principal1*
Triple negative breast cancer (TNBC) is a very aggressive type of breast cancer characterized by high cellular heterogeneity, metastatic capacity, and resistance to therapy. This is due to the increased proportion of cancer stem cells (CSCs) partly responsible for the initiation and progression of this type of cancer, and the lack of receptors to target. Therefore, it is a priority to find novel therapies targeting both chemotherapy-sensitive tumor cells and resistant cancer stem cells, to improve the prognosis of these patients. Gene profiling of TNBC revealed several subtypes with unique features, which has been a step forward in the search for new therapeutic modalities.
An Introduction to Breast Cancer
Author(s): Mohit Sharma; Sandeep Kaushik*
Cells are the basic unit of organisms. Cells grow and divide to form daughter cells as our body grows. Usually, old cells die and are replaced by new ones. Cancer begins when cells start to grow uncontrollably due to some genetic changes and form a mass of cells, called a tumor. A tumor can be malignant (cancerous) or benign. Breast cancer is one of the most common cancers in world after lung cancer. It is more common in women than men. In the year 2018, 2,088,849 new cases were reported (for both sexes). Breast cancer is detected by mammograms, sometimes even before it has spread to other parts of the body...
LKB1 A Novel Therapeutic Target in Breast Cancer- A Way Forward To a Less Aggressive Therapy
Author(s): Binafsha Manzoor Syed PhD; Jawaid Naeem Qureshi, FRCSIre, FRCSEd; Bikha Ram Devrajani, FCPS, FACP, FRCP
Breast cancer is a most common malignancy among females. There has been a number of biomarkers showing therapeutic potential, recently LKB1 gained much attention. LKB1 is an up-regulator of the AMPK pathway and manages cell energy metabolism. It also plays key role as tumour suppressor gene in association with p53. It has been associated with oestrogen receptor too...
